Call now for appointment

Dr. Arjun Kachhwaha

Consultant- Department of Hemato Oncology

About

Dr. Arjun Kachhwaha is an Clinical hematologist, hemato-oncologist & bone marrow transplant and CART physician

Qualification

  • DM (Clinical Hematology) (AIIMS)

  • M.D. (Gen Med) (AIIMS)

  • M.B.B.S. (AIIMS)

  • Clinical hematologist, hemato-oncologist & bone marrow transplant and CART physician

+ Appointment

Assistant Professor, Department of Clinical Hematology, AIIMS Jodhpur (18.02.2026 – 29.10.2026)

+ EDUCATION

  • Bachelor of medicine and Bachelor of surgery 2013-2018, All India institute of medical sciences (AIIMS), Raipur, Chhattisgarh, India.

  • Doctor of Medicine (MD) in Internal Medicine 2020-2022 All India institute of medical sciences (AIIMS), Jodhpur, Rajasthan, India.

  • Doctorate of Medicine (DM) in Clinical Haematology (Bronze medal in overall DM/Mch) 2023-2025 All India Institute of Medical Sciences (AIIMS), Rishikesh, India.

+ Expertise

  • Clinical hematology & hemato-oncology

  • Bone marrow transplant & CAR-T cell therapy

  • Acute and chronic leukemia (AML, ALL, CML) lymphoma

  • Myelodysplastic syndrome & myelofibrosis

  • Immune thrombocytopenia (ITP)

  • Infections and supportive care in hematological malignancies (febrile neutropenia, invasive fungal infection)

  • Clinical research: Co-Investigator in Phase I–III trials

+ Languages

  • Hindi

  • English

+ Contact

Medipulse, E-4, MIA, Basni-II, Jodhpur - 342005 (Raj.)

E-Mail Address: drarjunk95@gmail.com

OPD Timing (10:00 AM to 4:00 PM)

+ RESEARCH ACTIVITIES

  • Principal Investigator:
  1. (MD Internal Medicine thesis)
  2. (DM Clinical hematology thesis)

+ Publications

  • Acute Non-Promyelocytic Leukemia with Complex Karyotype and Novel t (15;17) (q21; p11.2)/B2M: RARA Fusion: A Case Report. Cardiovasc Hematol Disord Drug Targets. 2025 Aug 22. doi: 10.2174/011871529X378359250812115026. Epub ahead of print. PMID: 40873181.

  • Plasmablastic lymphoma presenting as sino-nasal mass in a child: a case report.https://doi.org/10.1016/j.phoj.2025.04.002

  • Pelvic Hematoma Revealing Chronic Myeloid Leukemia: Case Report of Two Patients. Cardiovasc Hematol Disord Drug Targets. 2025;25(1):73-77. doi: 10.2174/011871529X365410250131120926. PMID: 39950460.

  • Acute Myeloid Leukemia Presenting as Extensive Arterial and Venous Thrombosis: A Case Report. Cardiovasc Hematol Disord Drug Targets. 2024;24(4):266-270. doi: 10.2174/011871529X334859241016114027. PMID: 39482910.

  • Marked leukemoid reaction preceded the onset of meningitis: A case report. J Hematol Allied Sci. 2024;4:117-9. doi: 10.25259/JHAS_55_2024.

  • t (1;12) (p31; q13) cytogenetic abnormality in a patient of idiopathic hypereosinophilic syndrome: A case report. J Hematol Allied Sci. 2024;4:83-6. doi: 10.25259/JHAS_30_2024.

  • Infection Control Challenge: Kocuria rhizophila Bacteremia from A Peripherally Inserted Central Venous Catheter in A Pediatric Oncology Patient.https://doi.org/10.30654/mjcs.10049.

  • Rare Encounter: Rhizobium radiobacter Bacteraemia Coupled with Antimicrobial Resistance in an Acute Lymphoblastic Leukaemia Patient.https://doi.org/10.30654/mjcs.10048.

  • Measurable Residual Disease Results & Survival with Augmented Early Intensification Therapy in Intermediate-Risk & High-Risk Group Pediatric Acute Lymphoblastic Leukemia Patients Treated with ALL IC-BFM 2009 Protocol: A Single-Center Study from India.https://doi.org/10.1182/blood-2023-188377.

  • Delayed Compression Paralysis Following an Iliopsoas Hematoma 30 Days After Saw-Scaled Viper (Echis carinatus sochureki) Envenoming: A Case Report. Wilderness & Environmental Medicine. 2023;34(3):366-371. doi:10.1016/j.wem.2023.03.005.

  • Comparison of clinical characteristics and outcome in RT-PCR positive and false-negative RT-PCR for COVID-19: A Retrospective analysis. Infez Med. 2022 Sep 1;30(3):403-411. doi: 10.53854/liim-3003-8. PMID: 36148177; PMCID: PMC9448311.

  • Acute Myocardial Infarction in Hemophilia A with HIV and Hyperhomocysteinemia- A Rare Case Report. Cardiovasc Hematol Disord Drug Targets. 2022;22(1):3-5. doi: 10.2174/1871529X22666220126122458. PMID: 35081897.

  • Isolated Bilateral Abducens Palsy as a Presenting Feature of Multi-Infarct State: A Case Report. Cureus. 2022 Jan 16;14(1):e21286. doi: 10.7759/cureus.21286. PMID: 35186548; PMCID: PMC8846373.

  • Pseudo-pseudo Meigs' syndrome (PPMS) in chronic lupus peritonitis: a case report with review of literature. Mod Rheumatol Case Rep. 2021 Jul;5(2):300-305. doi: 10.1080/24725625.2021.1916160. Epub 2021 May 10. PMID: 33970813.

  • Concurrent acute myositis and Guillain-Barre syndrome in Cytomegalovirus infection - a rare case report. BMC Infect Dis. 2020 Oct 17;20(1):768. doi: 10.1186/s12879-020-05506-5. PMID: 33069216; PMCID: PMC7568349.

  • Kachhwaha A, Satadeve P, Gupta A, Singh N, Nath UK. Temporary Spontaneous Remission of Adult Acute Lymphoblastic Leukemia Associated with Scrub Typhus Infection. Cardiovasc Hematol Disord Drug Targets. 2025 Oct 22. doi: 10.2174/011871529X412564251003110936. Epub ahead of print. PMID: 41133832.

+ Awards and Accomplishments

  • Bronze Medal in overall DM/MCh, DM Clinical Haematology, AIIMS Rishikesh
  • Second Prize, poster presentation at Hematocon 2023 (venetoclax plus hypomethylating agent induction in AML patients not eligible for intensive chemotherapy)
  • Faculty member, Hematocon 2023
  • Oral presentation, Hematocon 2024 (generic venetoclax + HMA in newly diagnosed AML)
  • Poster presentations: Hope Asia 2023 (granulocyte transfusions in febrile neutropenia) and Hematocon 2024 (paediatric AML)
  • Co-Investigator in 6 industry-sponsored and multi-centre trials (MDS, CML, ITP, invasive fungal infection, lymphoma, myelofibrosis)

+ Co-Investigator

  • Phase 2a study of HT-6184 in subjects with IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anaemia
  • Phase IIIb, multi-centre, open-label, randomized study of tolerability and efficacy of Oral Asciminib versus Nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase.
  • Phase III, randomized double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or relapsed after first-line steroid treatment (VAYHIT2).
  • Prospective, Multi-centre, Active Post-Marketing Surveillance Study of Liposomal Amphotericin B (Amphonex® - Manufactured by Bharat Serums and Vaccines Ltd) in Patients with Invasive Fungal Infection who are refractory to or intolerant of conventional Amphotericin B therapy in Real World Clinical Practice (AMBeR).
  • phase 1, open-label, dose escalation, multicenter, first-in-human (FIH) study evaluating the safety, pharmacokinetics, and pharmacodynamics of oral AUR112 in patients with relapsed advanced lymphoma (ADITI-1)
  • randomised, controlled phase III study of Pacritinib versus physician's choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post-essential thrombocytopenia myelofibrosis with severe thrombocytopenia (platelet count <50,000 data-preserve-html-node="true"/mcl) (protocol PACIFICA PAC303)

+CONFERENCE PAPER PRESENTATIONS:

  • Poster presentation at Hematocon 2023 India - Effect of induction therapy with venetoclax plus hypomethylating agent in acute myeloid leukemia patients not eligible for intensive chemotherapy: a single-center experience- received second prize.
  • As a faculty member participating in Hematocon 2023 India.
  • Poster presentation in Hope Asia 2023 - efficacy of granulocyte transfusions in management of febrile neutropenia in patients of hematological malignancies:a single-centre retrospective study
  • Poster presentation in Hematocon 2024 India - Clinical profile & treatment results of paediatric acute myeloid leukemia patients: a single-center experience from AIIMS Rishikesh.
  • Oral presentation in Hematocon 2024 India- Real-world experience with generic venetoclax plus hypomethylating agent induction therapy in newly diagnosed acute myeloid leukemia patients in resource-limited setting: A single-center study from AIIMS Rishikesh.

Know more about Hemato oncology

Call now for appointment

Other relevant doctors that people search

Patient’s Testimonials

Testimonial
Kunal Jangid

Cancer changes your perspective towards life. When my son was diagnosed with cancer at the age of 13, we had lost hope because the internet said it was a rich man’s disease. But talking to Dr. Vinay Vyas of Medipulse, we got to know that affordable cancer treatment in Jodhpur was possible under Bhamashah Scheme. I was happy that my son could have his old life back. The Chemotherapy went on for sometime but the doctors stood with us throughout and took care of my son. The staff at medipulse was also there to meet our needs anytime. Thanks to Medipulse, my son is happy now.

Read more →
Mrinal Dave

I am a cancer survivor and watched my family’s savings go into my treatment. Cancer is an expensive treatment and knowing my restrictions, I had to find a hospital that provides the best care but at affordable charges. Many of relatives suggested Medipulse hospital, as it is the best cancer hospital in Jodhpur and is registered under Bhamashah Scheme. I was under the consultation of Dr Vinay Vyas, who not only helped me with regular screenings but also helped us in finding a package that was affordable for us. He is an expert in Breast Cancer with decades of experience. Thankfully, I got my treatment done under bhamashah scheme for cancer at Medipulse.

Read more →
Ambika Jain

My husband was diagnosed with stage I lung cancer by the team of Medipulse Hospital. We were very shocked and disturbed by this news. But the team of doctors at Medipulse suggested us to start the treatment as soon as possible. After only a few months of therapy, my husband completely recovered from cancer. Medipulse is undoubtedly the best cancer hospital in Jodhpur, it saved the life of my husband!

Read more →
Priyanka Vyas

Thanks to the specialists at Medipulse Hospital that my fathers cancer was diagnosed at the first stage. While my family got fear, the surgeon suggested use the best treatment to free my dad from cancer. And only in a few months of treatment the reports showed no sign of cancer. Medipulse is for sure the best cancer hospital in Jodhpur.

Read more →
Blog
Why Should Smoking Be Abolished From Your Life: Cancer Spotlight
Why Should Smoking Be Abolished From Your Life: Cancer Spotlight

According to a survey by WHO, approximately 120 million Indians are smokers, which makes up about 12% of the world’s total population of smokers. Not only is that an alarming state, but it is also a significant concern for the overall health of the nation. There is no doubt smoking poses a threat to the one smoking. But, it is also a substantial threat to the people exposed to the smoke.

Read more →
How Effective Is Vegan Diet For Cancer Patients
How Effective Is Vegan Diet For Cancer Patients

Cancer is one of the major threats to human health in the current time. Characterized by the uncontrolled growth of abnormal cells in the human body, cancer creates tumour tissue that affects the growth of other healthy cells by hijacking their nutrition. Cancer cells can also travel to other parts of the body and create tumours, facilitating the overall growth of cancer in the body. One of the most concerning factors about cancer, however, is the increasing incidence rate of the diseases in the current world.

Read more →
Go Back To Doctors